Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Jul;67(7):674-82.
doi: 10.1001/archgenpsychiatry.2010.63. Epub 2010 May 3.

Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial

Shaun M Eack  1 , Gerard E Hogarty, Raymond Y Cho, Konasale M R Prasad, Deborah P Greenwald, Susan S Hogarty, Matcheri S Keshavan
Affiliations
Randomized Controlled Trial

Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial

Shaun M Eack et al. Arch Gen Psychiatry. 2010 Jul.

Abstract

Context: Cognitive rehabilitation has shown efficacy in improving cognition in patients with schizophrenia but the underlying neurobiologic changes that occur during these treatments and support cognitive improvement are not well known.

Objective: To examine differential changes in brain morphology in early course schizophrenia during cognitive rehabilitation vs supportive therapy.

Design: Randomized controlled trial.

Setting: An outpatient research clinic at a university-based medical center that provides comprehensive care services for patients with severe mental illness.

Patients: A total of 53 symptomatically stable but cognitively disabled outpatients in the early course of schizophrenia or schizoaffective disorder.

Interventions: A 2-year trial with annual structural magnetic resonance imaging and cognitive assessments. Cognitive enhancement therapy is an integrated approach to the remediation of cognitive impairment in schizophrenia that uses computer-assisted neurocognitive training and group-based social-cognitive exercises. Enriched supportive therapy is an illness management approach that provides psychoeducation and teaches applied coping strategies.

Main outcome measures: Broad areas of frontal and temporal gray matter change were analyzed with longitudinal, voxel-based morphometry methods using mixed-effects models followed by volumetric analyses of regions that demonstrated significant differential changes between treatment groups.

Results: Patients who received cognitive enhancement therapy demonstrated significantly greater preservation of gray matter volume over 2 years in the left hippocampus, parahippocampal gyrus, and fusiform gyrus, and significantly greater gray matter increases in the left amygdala (all corrected P < .04) compared with those who received enriched supportive therapy. Less gray matter loss in the left parahippocampal and fusiform gyrus and greater gray matter increases in the left amygdala were significantly related to improved cognition and mediated the beneficial cognitive effects of cognitive enhancement therapy.

Conclusion: Cognitive enhancement therapy may offer neurobiologic protective and enhancing effects in early schizophrenia that are associated with improved long-term cognitive outcomes.

Trial registration: ClinicalTrials.gov NCT00167362.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest with this research.

Figures

Figure 1
Figure 1
Two-Year Participant Flow in a Randomized Trial of Cognitive Enhancement Therapy for Early Course Schizophrenia.
Figure 2
Figure 2
Regions of Differential Gray Matter Change Among Participants Receiving Cognitive Enhancement Therapy Versus Enriched Supportive Therapy.
Figure 3
Figure 3
Relations Between Neurobiologic and Cognitive Change During Two Years of Cognitive Enhancement Therapy or Enriched Supported Therapy.
See this image and copyright information in PMC

References

    1. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: A quantitative review of the evidence. Neuropsychology. 1998;12(3):426–445. - PubMed
    1. Penn DL, Corrigan PW, Bentall RP, Racenstein J, Newman L. Social cognition in schizophrenia. Psychol Bull. 1997;121(1):114–132. - PubMed
    1. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: Are we measuring the right stuff. Schizophr Bull. 2000;26(1):119–136. - PubMed
    1. Couture SM, Penn DL, Roberts DL. The Functional Significance of Social Cognition in Schizophrenia: A Review. Schizophr Bull. 2006;32(Suppl1):S44–63. - PMC - PubMed
    1. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res. 2004;72(1):41–51. - PubMed

Publication types

MeSH terms

Associated data